These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22790350)

  • 1. Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial.
    Witthöft T; Möller B; Wiedmann KH; Mauss S; Link R; Lohmeyer J; Lafrenz M; Gelbmann CM; Hüppe D; Niederau C; Alshuth U
    J Viral Hepat; 2007 Nov; 14(11):788-96. PubMed ID: 17927615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C.
    Hauser G; Awad T; Thorlund K; Štimac D; Mabrouk M; Gluud C
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005642. PubMed ID: 24585451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS.
    Dresch KF; Mattos AA; Tovo CV; Onofrio FQ; Casagrande L; Feltrin AA; Barros IC; Almeida PR
    Rev Inst Med Trop Sao Paulo; 2016; 58():37. PubMed ID: 27253739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective.
    Tran HA; Jones TL; Ianna EA; Foy A; Reeves GE
    Endocr Pract; 2013; 19(2):292-300. PubMed ID: 23186968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated summaries of serious adverse events in the hepatitis C antiviral long-term treatment against cirrhosis trial.
    Bell MC; Robuck PR; Wright EC; Mihova MS; Hofmann C; De Santo JL; Milstein SL; Richtmyer PA; Shelton JL; Cormier M; King DL; Park CJ; Molchen WA; Park Y; Kelley M
    Clin Trials; 2009 Dec; 6(6):618-27. PubMed ID: 19889888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis.
    Alavian SM; Behnava B; Tabatabaei SV
    Hepat Mon; 2010; 10(2):121-31. PubMed ID: 22312385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated-interferon alpha (PEG-IFNα)-induced interstitial lung disease in a patient with chronic hepatitis B: A case report and literature review.
    Shi M; Wang S; Ren Y; Zhao L; Liu M; Yang L; Yang T
    Int J Clin Pharmacol Ther; 2024 Aug; 62(8):386-394. PubMed ID: 38699975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of ribavirin and interferon-α therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study.
    Li H; Xiong N; Li C; Gong Y; Liu L; Yang H; Tan X; Jiang N; Zong Q; Wang J; Lu Z; Yin X
    Int J Infect Dis; 2021 Mar; 104():641-648. PubMed ID: 33515771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 1 Diabetes Mellitus Associated with Pegylated Interferon-α Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature Review.
    Oka R; Hiroi N; Shigemitsu R; Sue M; Oshima Y; Yoshida-Hiroi M
    Clin Med Insights Endocrinol Diabetes; 2011; 4():39-45. PubMed ID: 22879793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world study on the use of pegylated interferon alpha-2a for treatment of mycosis fungoides/Sézary syndrome using Time to Next Treatment as a measure of clinical benefit: An EORTC CLTG study.
    Mitsunaga K; Bagot M; Ram-Wolff C; Guenova E; von Gugelberg C; Hodak E; Amitay-Laish I; Papadavid E; Jonak C; Porkert S; Scarisbrick J; Applewaite R; Beylot-Barry M; Nicolay J; Quaglino P; Sanches JA; Cury-Martins J; Lora-Pablos D; Ortiz P
    Br J Dermatol; 2024 Apr; ():. PubMed ID: 38596857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis.
    Bewersdorf JP; Giri S; Wang R; Podoltsev N; Williams RT; Rampal RK; Tallman MS; Zeidan AM; Stahl M
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e712-e723. PubMed ID: 32669244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Type I Interferon Antiviral Effects in Respiratory and Reemerging Viral Infections.
    Acosta PL; Byrne AB; Hijano DR; Talarico LB
    J Immunol Res; 2020; 2020():1372494. PubMed ID: 32455136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity.
    Hijano DR; Vu LD; Kauvar LM; Tripp RA; Polack FP; Cormier SA
    Front Immunol; 2019; 10():566. PubMed ID: 30972063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C Genotype Prevalence in Monastir Region, Tunisia: Correlation between 5' Untranslated Region (5'UTR), Non-structural 5B (NS5B), and Core Sequences in HCV Subtyping.
    Souii A; Elargoubi A; Fallecker C; Mastouri M; Drouet E
    Curr Microbiol; 2016 Sep; 73(3):324-334. PubMed ID: 27189386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes and Hepatitis C: A Two-Way Association.
    Hammerstad SS; Grock SF; Lee HJ; Hasham A; Sundaram N; Tomer Y
    Front Endocrinol (Lausanne); 2015; 6():134. PubMed ID: 26441826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection.
    Asada A; Shioya M; Osaki R; Nishimura T; Takeuchi T; Okumura Y; Andoh A
    Biomed Rep; 2015 Mar; 3(2):247-253. PubMed ID: 26075078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study.
    Nishiguchi S; Enomoto H; Aizawa N; Nishikawa H; Osaki Y; Tsuda Y; Higuchi K; Okazaki K; Seki T; Kim SR; Hongo Y; Jyomura H; Nishida N; Kudo M
    J Gastroenterol; 2014 Mar; 49(3):492-501. PubMed ID: 23543311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C.
    Minami T; Kishikawa T; Sato M; Tateishi R; Yoshida H; Koike K
    J Gastroenterol; 2013 Feb; 48(2):254-68. PubMed ID: 22790350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis.
    Druyts E; Thorlund K; Wu P; Kanters S; Yaya S; Cooper CL; Mills EJ
    Clin Infect Dis; 2013 Apr; 56(7):961-7. PubMed ID: 23243171
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.